Buys
Open market- Shares
- Avg price
- Total value
Jonathan Zalevsky - Chief R&D Officer at NEKTAR THERAPEUTICS
Issuer-level insider activity
- Role
- Chief R&D Officer
- Issuer ticker
- NKTR on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Jonathan Zalevsky in NEKTAR THERAPEUTICS
Sells
Open market- Shares
- -18,828
- Avg price
- $54.87
- Total value
- -$1,033,087
Net
Past year- Shares
- -18,828
- Share %
- -100%
- Total value
- -$1,033,087
Reported holdings for Jonathan Zalevsky in NEKTAR THERAPEUTICS
Form 4 holding
Chief R&D Officer
NEKTAR THERAPEUTICS
- Security class
- Common Stock
- Shares / value
- 9,756
- Estimated value
- $682,920
- Report date
- 30 Jun 2026
- Price
- $70.00
- Ownership
- Direct
Form 4 holding
Chief R&D Officer
NEKTAR THERAPEUTICS
- Security class
- Stock Option
- Shares / value
- 16,500
- Estimated value
- Report date
- 24 Jul 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Jonathan Zalevsky in NEKTAR THERAPEUTICS
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.